Baiteng Zhao

1.2k total citations
30 papers, 985 citations indexed

About

Baiteng Zhao is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Molecular Biology. According to data from OpenAlex, Baiteng Zhao has authored 30 papers receiving a total of 985 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Radiology, Nuclear Medicine and Imaging and 10 papers in Molecular Biology. Recurrent topics in Baiteng Zhao's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Lymphoma Diagnosis and Treatment (6 papers). Baiteng Zhao is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Lymphoma Diagnosis and Treatment (6 papers). Baiteng Zhao collaborates with scholars based in United States. Baiteng Zhao's co-authors include Phillip D. Bowman, Tae Hyung Han, Salomon Stavchansky, Robert A. Bowden, Megan M. O’Meara, Luis A. Cubano, Daniel J. DeAngelo, Jonathan G. Pabalan, Marian L. Lewis and Amir T. Fathi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Baiteng Zhao

29 papers receiving 956 citations

Peers

Baiteng Zhao
Steven P. Piccoli United States
Jiandong Zhang China
Julia Calzada‐Wack Germany
Marie‐Françoise Bourgeade France
Jean Harb France
F A Firgaira Australia
Yaomin Xu United States
Suzanne J. Suchard United States
Michael Ford United States
ML Sherman United States
Steven P. Piccoli United States
Baiteng Zhao
Citations per year, relative to Baiteng Zhao Baiteng Zhao (= 1×) peers Steven P. Piccoli

Countries citing papers authored by Baiteng Zhao

Since Specialization
Citations

This map shows the geographic impact of Baiteng Zhao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Baiteng Zhao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Baiteng Zhao more than expected).

Fields of papers citing papers by Baiteng Zhao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Baiteng Zhao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Baiteng Zhao. The network helps show where Baiteng Zhao may publish in the future.

Co-authorship network of co-authors of Baiteng Zhao

This figure shows the co-authorship network connecting the top 25 collaborators of Baiteng Zhao. A scholar is included among the top collaborators of Baiteng Zhao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Baiteng Zhao. Baiteng Zhao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Xiao, Yang, Lei Wang, Wanwan Shen, et al.. (2023). 1406 A novel PTK7-directed antibody-drug conjugate (ADC) PRO1107 demonstrated broad antitumor activity with a promising safety profile in preclinical models. SHILAP Revista de lepidopterología. A1564–A1564. 1 indexed citations
2.
Wang, Lei, Haidong Liu, Chang Zhou, et al.. (2023). Abstract 2637: Novel folate receptor alpha-directed antibody-drug conjugate PRO1184 demonstrates broad antitumor activity with a promising safety profile in preclinical models. Cancer Research. 83(7_Supplement). 2637–2637. 2 indexed citations
3.
4.
Stein, Eytan M., Roland B. Walter, Harry P. Erba, et al.. (2017). A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 131(4). 387–396. 137 indexed citations
5.
Li, Hong, Tae Hyung Han, Naomi Hunder, Graham Jang, & Baiteng Zhao. (2017). Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies. The Journal of Clinical Pharmacology. 57(9). 1148–1158. 48 indexed citations
6.
Zhao, Baiteng, Robert Chen, Owen A. O’Connor, et al.. (2016). Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment. British Journal of Clinical Pharmacology. 82(3). 696–705. 47 indexed citations
7.
Stein, Anthony S., Roland B. Walter, Harry P. Erba, et al.. (2015). A Phase 1 Trial of SGN-CD33A As Monotherapy in Patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood. 126(23). 324–324. 25 indexed citations
8.
Han, Tae Hyung & Baiteng Zhao. (2014). Absorption, Distribution, Metabolism, and Excretion Considerations for the Development of Antibody-Drug Conjugates. Drug Metabolism and Disposition. 42(11). 1914–1920. 72 indexed citations
9.
Tannir, Nizar M., Andres Forero‐Torres, Radhakrishnan Ramchandren, et al.. (2014). Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Investigational New Drugs. 32(6). 1246–1257. 97 indexed citations
10.
Albertson, Tina, et al.. (2014). Abstract DDT01-04: SGN-CD19A: A novel Anti-CD19 antibody drug conjugate. Cancer Research. 74(19_Supplement). DDT01–4. 1 indexed citations
11.
Stein, Eytan M., Anthony S. Stein, Roland B. Walter, et al.. (2014). Interim Analysis of a Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia (AML). Blood. 124(21). 623–623. 26 indexed citations
12.
Coveler, Andrew L., Daniel D. Von Hoff, Andrew H. Ko, et al.. (2013). A phase I study of ASG-5ME, a novel antibody-drug conjugate, in pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 31(4_suppl). 176–176. 7 indexed citations
13.
Thompson, John A., Elisabeth I. Heath, Stephen M. Ansell, et al.. (2011). The effect of SGN-75, a novel antibody–drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): A phase I study.. Journal of Clinical Oncology. 29(15_suppl). 3071–3071. 12 indexed citations
14.
Traynor, Anne M., Glenn Liu, Keith T. Flaherty, et al.. (2010). Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 67(2). 305–314. 73 indexed citations
15.
Wang, Xinyu, Salomon Stavchansky, Baiteng Zhao, et al.. (2008). Cytoprotection of human endothelial cells from menadione cytotoxicity by caffeic acid phenethyl ester: The role of heme oxygenase-1. European Journal of Pharmacology. 591(1-3). 28–35. 36 indexed citations
16.
Yao, Zhenling, Baiteng Zhao, Eric P. Hoffman, et al.. (2007). Application of Scaling Factors in Simultaneous Modeling of Microarray Data from Diverse Chips. Pharmaceutical Research. 24(4). 643–649. 4 indexed citations
17.
Kiang, Juliann G., Phillip D. Bowman, Xinyue Lu, et al.. (2006). Geldanamycin prevents hemorrhage-induced ATP loss by overexpressing inducible HSP70 and activating pyruvate dehydrogenase. American Journal of Physiology-Gastrointestinal and Liver Physiology. 291(1). G117–G127. 22 indexed citations
18.
Kiang, Juliann G., Phillip D. Bowman, Brian Wu, et al.. (2004). Geldanamycin treatment inhibits hemorrhage-induced increases in KLF6 and iNOS expression in unresuscitated mouse organs: role of inducible HSP70. Journal of Applied Physiology. 97(2). 564–569. 45 indexed citations
19.
Zhao, Baiteng, Salomon Stavchansky, Robert A. Bowden, & Phillip D. Bowman. (2003). Effect of interleukin-1β and tumor necrosis factor-α on gene expression in human endothelial cells. American Journal of Physiology-Cell Physiology. 284(6). C1577–C1583. 67 indexed citations
20.
Zhao, Baiteng, Robert A. Bowden, Salomon Stavchansky, & Phillip D. Bowman. (2001). Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays. American Journal of Physiology-Cell Physiology. 281(5). C1587–C1595. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven P. Piccoli Breakdown of academic impact, for papers by Jiandong Zhang Breakdown of academic impact, for papers by Julia Calzada‐Wack Breakdown of academic impact, for papers by Marie‐Françoise Bourgeade Breakdown of academic impact, for papers by Jean Harb Breakdown of academic impact, for papers by F A Firgaira Breakdown of academic impact, for papers by Yaomin Xu Breakdown of academic impact, for papers by Suzanne J. Suchard Breakdown of academic impact, for papers by Michael Ford Breakdown of academic impact, for papers by ML Sherman
Rankless by CCL
2026